Hyperprogression During Immunotherapy: Teasing Out the Mechanism
A preclinical study highlights the potential role the Fc receptor may play in mediating hyperprogressive disease, but further study is needed.
Lung Cancer
Prophylactic Cranial Irradiation Not Associated With Improved OS in Locally Advanced NSCLC
Prophylactic brain irradiation was associated with a significant improvement in disease-free survival and a significant reduction in likelihood of developing brain metastases.
Tecentriq Plus Chemotherapy Approved for Initial Treatment of Extensive-Stage Small Cell Lung Cancer
The Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab; Genentech), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Genomic Profiling May Detect Lung Cancer Early
Researchers say they can distinguish between lesions that are benign and those that could become invasive — but the technology required is not yet used routinely.
Genomic Characterization of Chemoresistant Metastatic Small Cell Lung Cancer
Whole-genome sequencing of tumor specimens from patients with chemoresistant SCLC showed evidence of the deletion of multiple tumor suppressor genes.
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
ALK‐ vs EGFR‐Positive NSCLC: CT Imaging and Clinical Characteristics
NSCLC characterized by ALK or EGFR molecular alterations produced different findings on CT scan images.
Genomic Profiling Using Guardant 360 Cell-Free DNA-Based Assay vs Tumor-Based Genotyping Assays in Advanced NSCLC
The Guardant360 assay is as effective as traditional tumor-based genotyping assays in identifying genomic alterations, according to researchers.
Next post in AACR 2019
